Neurocrine's total assets for Q3 2025 were $4.27B, an increase of 9.66% from the previous quarter. NBIX total liabilities were $1.26B for the fiscal quarter, a 5.57% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.